top of page
Solid Lipid Nanoparticle (SLNP) Nammisome formulated with a Doxorubicin prodrug (IC1) and Toll Receptor 7 agonist prodrug (TR12) incorporated
Why a Doxorubicin Prodrug? IC1 is a reformulated prodrug of Doxorubicin with an improved therapeutic window and improved drug stability, efficacy, and safety. The dual drug delivery of IC1 with a synergistic immunotherapy using the Solid Lipid Nanoparticle platform can enhance the immunogenic cell death initiated by the release of IC1.
Why a TLR-7 Agonist Prodrug? Toll-like receptor 7 agonists are clinically validated to have anti-tumor activity but are generally too potent to administer as free drugs. Incorporation of the prodrug in a Nammisome targets the activity to tumors while reducing systemic activity, allowing for safer delivery of effective doses.
Target Indications: While the immune mechanisms targeted by IC1 and TR12 are independent of cancer type, the mechanism of selective tumor delivery of Nammisomes is dependent on the presence of a tumor mass (as opposed to dispersed cells). This suggests that NTI-121 may be effective when administered to solid tumors.
Solid Lipid Nanoparticle
IC1: Doxorubicin Prodrug
TR12: TLR-7 Agonist Prodrug
NTI-121: Anti-Tumor Efficacy in Vivo
Demonstrated Tumor Growth Inhibition Vs. Wide Range of Tumor Indications
Tumor Growth Regression Observed in Liver and Pancreatic Murine Tumor Models
bottom of page